A 52-week, randomised, double-blind, parallel-group, multi-centre, phase IIIB study comparing the long term safety of SYMBICORTO pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (greater than or equal to12 years) African American subjects with asthma.

Trial Profile

A 52-week, randomised, double-blind, parallel-group, multi-centre, phase IIIB study comparing the long term safety of SYMBICORTO pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (greater than or equal to12 years) African American subjects with asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2012

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 May 2012 Results from this trial published in the Journal of Allergy & Clinical Immunology in May 2012, according to an AstraZeneca media release. Top-line tolerability results were reported also in the media release.
    • 06 Mar 2012 Long-term cardiovascular safety results presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 27 Oct 2011 Results presented at the 77th Annual Meeting of the American College of Chest Physicians: Chest 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top